Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae (MASTERMINDRING)

Duke University

Status: Enrolling

Conditions: Neisseria Gonorrheae Infection

Treatments: Diagnostic Test: Investigational Reflex Test 3; Diagnostic Test: Investigational Reflex Test 2; Diagnostic Test: Investigational Reflex Test 1

Study type: Observational

Funder types: Other; Industry; NIH

Identifiers

NCT06815536

Pro00113379

UM1AI104681 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The goal of this study is to learn if a few investigational tests can correctly find the gene mutation (mutant allele gyrA 91F) that predicts ciprofloxacin resistance in clinical specimens that harbor Neisseria gonorrhoeae. The main question the study aims to answer:

Can the investigational reflex test find the correct gene mutation (Neisseria gonorrhoeae gyrA 91F or gyrA 91S) as compared to the sequenced result?

Specimens that are collected for routine clinical care and harbor Neisseria gonorrhoeae will be evaluated in this study.

Full description

This is a prospective, multi-center, cross-sectional study using consecutive clinical specimens that are collected for routine clinical care and test positive for N. gonorrhoeae using an FDA-cleared molecular assay. The study evaluates the diagnostic accuracy of multiple investigational reflex tests to detect the mutant allele gyrA 91F that predicts ciprofloxacin resistance in N. gonorrhoeae, as compared to a reference standard of Sanger sequencing of the gyrA codon 91. Specimens will be tested via a reference standard of Sanger sequencing and one investigational reflex test. The target sample size is 311 urine specimens, 496 vaginal swab specimens, and 469 pharyngeal specimens, for each investigational reflex test.

Enrollment: 3,291 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Be N. gonorrhoeae-positive on an FDA-cleared molecular assay
• Have sufficient N. gonorrhoeae-positive specimen volume for testing using the corresponding investigational reflex test and genetic sequencing
• Undergo proper handling and storage conditions

Exclusion criteria

• The N. gonorrhoeae-positive specimen media is not compatible with the investigational reflex test(s) at the laboratory site
• The N. gonorrhoeae-positive specimen is not clearly labeled by the laboratory to link to basic epidemiologic data (age, sex) and source

Trial design

3,291 participants in 3 patient groups

Urine

Description:

Investigational Reflex Test performed to detect the mutant gyrA 91F allele or the wildtype gyrA 91S allele using urine samples.

Treatment:

Diagnostic Test: Investigational Reflex Test 1

Diagnostic Test: Investigational Reflex Test 2

Diagnostic Test: Investigational Reflex Test 3

Vaginal Swab

Description:

Investigational Reflex Test performed to detect the mutant gyrA 91F allele or the wildtype gyrA 91S allele using vaginal swabs.

Treatment:

Diagnostic Test: Investigational Reflex Test 1

Diagnostic Test: Investigational Reflex Test 2

Diagnostic Test: Investigational Reflex Test 3

Pharyngeal Swabs

Description:

Investigational Reflex Test performed to detect the mutant gyrA 91F allele or the wildtype gyrA 91S allele using pharyngeal swabs.

Treatment:

Diagnostic Test: Investigational Reflex Test 1

Diagnostic Test: Investigational Reflex Test 2

Diagnostic Test: Investigational Reflex Test 3